The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. [electronic resource]
Producer: 20070917Description: 1096-101 p. digitalISSN:- 1462-0324
- Acute Disease
- Computer Simulation
- Cost-Benefit Analysis
- Cyclophosphamide -- administration & dosage
- Day Care, Medical -- economics
- Drug Costs
- Humans
- Immunosuppressive Agents -- economics
- Infusions, Intravenous
- Lupus Erythematosus, Systemic -- drug therapy
- Lupus Nephritis -- drug therapy
- Models, Economic
- Mycophenolic Acid -- analogs & derivatives
- Prednisolone -- economics
- Quality-Adjusted Life Years
- State Medicine -- economics
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.